

# Index to Volume 9

## Author Index

- Abelson, T. I., 799  
Abrutyn, E., 388  
Achtman, M., 665  
Alford, R. H., 1079  
Almudallal, D. S., 531  
Alvarez, S., 884, 1140  
Aly, R., S341  
Apicella, M. A., 1, 176  
Appleman, M., 655  
Apuzzio, J. J., S211  
Arathoon, E., S77  
Arias, I., S100  
Avorn, J., S286  
Bach, M. C., 130  
Baddour, L. M., 1168  
Balligand, G., 64  
Bar-Sela, A., 1192  
Barbaro, D. J., 124  
Bardelay, G., S286  
Barth, S. S., 124  
Batchelor, F. R., S297  
Baughn, R. E., S372  
Baumgartner, J. D., 194  
Baus, F., S602  
Beachey, E. H., S475  
Beck, L., S512  
Beckurts, T., S585  
Belaustegui, A. R.-N., S121  
Bennett, J. E., 398  
Bergan, T., 713  
Berger, S. A., 54  
Berk, S. L., 1140  
Berry, G. R., 578  
Bibler, M. R., 790  
Blake, J. B., 1044  
Blake, L. A., 562  
Blake, P. A., 1065  
Bodhidatta, L., 841  
Bonifaz, A., S100  
Boogaerts, M. A., S94  
Borelli, D., S57  
Borgers, M., S33  
Borghys, A., S104  
Bouza, E., 810  
Brade, H., S527  
Brade, L., S527  
Brandenburg, K., S527  
Brennan, M. J., S467  
Brooks, R. G., 754, 775, 1055  
Brown, K. M., S594  
Brown, K. R., 1095  
Brunham, R. C., 846  
Buggy, B. P., 228  
Burke, J. P., S231, S313  
Burks, M. F., S44, S490  
Búzon, L., 1201  
Caffarena, R. M., 386  
Calandra, G. B., 1095  
Calderón-Márquez, J. J., S143  
Calderone, R. A., S400  
Cano, L. E., S51  
Carlin, S., 16  
Cartelli, N. A., 16  
Cauwenbergh, G., S43, S94, S146  
Chakraborty, T., S456  
Chase, R. A., 329  
Chassy, B. M., S467  
Check, W. A., 987  
Chedid, L. A., S630  
Chernin, E., 625  
Cherubin, C. E., 655  
Christensen, G. D., 1168  
Cisar, J. O., S467  
Clarkson, J. A., 866  
Clasener, H. A. L., 295  
Clayton, Y. M., S114  
Cohen, N. H., 1163  
Cohen, S. H., 917  
Col, N. F., S232  
Cornelis, G., 64  
Corwin, D., S450  
Courtney, H. S., S351, S475  
Crowe, B. A., 665  
Cruz, J. M., 88  
Cryz, S. J., Jr., S644  
Dall, L., 795  
Dallas, W. S., 544, S490  
Damte, B., 140  
Danker, W. M., 743  
Danner, R. L., 265  
Davey, R. T., Jr., 110  
Davis, C. E., 743  
Davis, D. S., S639  
Davis, K. M., 130  
De Coster, R., S43  
De Dier, A.-M., S146  
de Doncker, P., S146  
de Jong-Leuveninck, J., S527  
De Ovando, F., S64  
De Veylder, H., S104  
Degreaf, H., S104  
Desrosiers, R. C., 438  
Difonzo, E., S109  
Dispensiere, B. R., S211  
Dominguez, E. A., 1192  
Donkersloot, J. A., S467  
Dorfman, R. F., 754  
Dowell, V. R., Jr., 737  
Downs, N. J., 693  
Drabick, J. J., 1087  
Drouhet, E., S4, S71  
Drutz, D. J., 392, 417  
Duperval, R., 376  
Dupont, B., S4, S71  
DuPont, H. L., 447  
Duprez, K., S104  
Dylewski, J. S., 578  
Earnest, M. P., 961  
Echeverria, P., 841  
Ehrenkranz, N. J., 222  
El-Sadr, W., 660  
Eng, R., 655  
Engeset, A., 713  
Estrada, R. A., S128  
Falk, W., S602  
Falkow, S., S450  
Fan, M.-Y., 823  
Feder, H. M., Jr., 783  
Feldman, R. M., 134  
Fetchick, R., S87  
Fierer, J., 743  
Filley, C. M., 961  
Fine, P. E. M., 866  
Finogold, S. M., 1150  
Finkelstein, R. A., 544, S490  
Fishbein, D. B., 935  
FitzGerald, D. J. P., S644  
Flad, H.-D., S527  
Flohé, L., S553  
Flores, V., S134  
Folb, P. I., S261  
Foshee, S., S87  
Frame, P. T., 595  
Frank, M. M., S537  
Frengley, D., 140  
Fulton, D., 16  
Fürer, E., S644  
Galanos, C., S599  
Galarza, S., S134  
Galimberti, R. L., S47, S134  
Gallemore, G., 1186  
Gallis, H. A., 581  
Ganer, A., S77  
Ganesh, V. V., S211  
Garcia de la Torre, M., 810  
Garelik, J. P., 1095  
Garvey, G. J., 1001  
Germanier, R., S644  
Gianis, J. T., 790  
Giertz, H., S553  
Gigliotti, F., S639  
Glauser, M. P., 194  
Glück, D., S599  
Gobernado, J., 810  
Goebel, W., S456  
Goic, A., S270  
Gomez, I., S51  
Gordon, D. L., 97

- Goyvaerts, H., S146  
 Graybill, J. R., S1, S87  
 Greenwood, B., 176  
 Gregg, C. R., 1120  
 Grek, A. J., 961  
 Griffiss, J. McL., 176  
 Grossman, J. E., S420  
 Guerra, C., 1006  
 Guerrant, R. L., S270  
 Guerrero, A., 810  
 Gullberg, R. M., 369  
 Haber, M. H., 329  
 Hacker, J., S456  
 Hadfield, T. L., 1006  
 Hager, H., 1140  
 Hagmann, W., S580  
 Hall, A., 1079  
 Hamill, R. J., S360  
 Hammer, C., S537  
 Harrelson, J. M., 581  
 Hartman, B. J., 265  
 Hautanen, A., S404  
 Hay, R. J., S1, S114  
 Hayes, S. F., S450  
 Helmick, C. G., 511  
 Herxheimer, A., S286  
 Heykants, J., S43  
 Hicklin, H., 884  
 Hildner, W. K., S639  
 Hill, G. B., 581  
 Hindler, J., S177  
 Hodges, G. R., 693  
 Hof, H., S456  
 Holmberg, S. D., 1065  
 Hopewell, P. C., 1163  
 Hostetter, M. K., 97  
 Hrdy, D. B., 461, 1109  
 Huhle, B., S456  
 Hummer, D., 54, 1102  
 Hutchins, G. M., 1013  
 Ingham, H. R., 659  
 Isberg, R., S450  
 Iverson, G., 787  
 Jacob, C. O., S44, S490  
 Jacobs, M. R., 799  
 Jann, B., S517  
 Jann, K., S517  
 Janssen, P. A. J., S15  
 Jenny, D. B., 787  
 Jensen, D., 329  
 Jivani, A., S270  
 Johnson, A. G., S512  
 Johnson, C. C., 1150  
 Johnson, C. E., 16  
 Joiner, K., S537  
 Joosten, E., S94  
 Jordan, G. W., 917  
 Julkunen, I., S404  
 Junker, D., S439  
 Kaplan, K., 226  
 Karp, J. E., 1013  
 Kass, E. H., S482  
 Kathariou, S., S456  
 Katz, S. L., 334  
 Kaufmann, S. H. E., S650  
 Kawahara, K., S527  
 Kaye, D., 388  
 Keane, W. F., 604  
 Keppler, D., S580  
 Keski-Oja, J., S404  
 Keusch, G. T., 428  
 Khatib, R., 382  
 Khodeir, S. M., 531  
 Kiehn, T. E., 1201  
 Kim, C. H., 16  
 Kistler, G., 329  
 Kohler, P. T., 1095  
 Koren, K., S47  
 Kubanek, B., S599  
 Kuhn, M., S456  
 Kunin, C. M., S270  
 Lambert, R., 376  
 Laroche, Y., 64  
 Lary, C. H., 562  
 Lasch, H.-G., S570  
 Latour, A. H., 578  
 Lavalie, P., S64  
 Lederman, M. M., 799  
 Lee, C.-J., 494  
 Letendre, P. W., 787  
 Letvin, N. L., 438  
 Leven, M. L., 369  
 Lévesque, R., 376  
 Levin, S., 329  
 Levit, S., S341  
 Levitz, R. E., S160  
 Levy, S. B., S231, S313  
 Lindner, B., S527  
 Lipton, H. L., S270  
 Liss, R. H., S297  
 Lister, J., 421  
 Liu, Q.-H., 823  
 Ljungberg, B., 250  
 Lo, B., 1163  
 Loppnow, H., S527  
 Lorenz, W., S585  
 Louria, D. B., S211  
 Luce, J. M., 1163  
 Lüderitz, T., S527  
 Ludwig, D. S., S44, S490  
 Luelmo, F., 427  
 Lupski, J. R., 357  
 Lüscher, E. F., S546  
 Lyle, M. A., 519  
 Mackowiak, P. A., 124  
 Mäkelä, P. H., 176  
 Maloney, J. M., 1120  
 Mandell, W. F., 1001  
 Manian, F. A., 1120  
 Männel, D. N., S602  
 Marafie, A. A., 531  
 Marchant, C. D., 16  
 Mariën, K., S104  
 Markowitz, N., S218  
 Maroske, D., S585  
 Martin, R. R., S270  
 Martone, W. J., 737  
 Matzke, G., 604  
 McCabe, R. E., 754, 1055  
 McCuskey, P. A., S616  
 McCuskey, R. S., S616  
 McDade, J. E., 935  
 McDermott, C., 891  
 McGraw, D. J., 1013  
 McKeown-Longo, P. J., S322  
 McKinney, R. E., Jr., 334  
 McLaurin, R. L., 595  
 McNeil, M. M., 737  
 Medoff, G., 403  
 Mendez, F. J., 1038  
 Mendez, J., 382  
 Mendoza, M. C., 1038  
 Mergenhausen, S. E., S467  
 Merte, H., S585  
 Merz, W. G., 1013  
 Meunier, F., 408  
 Miller, A. M., S211  
 Miller, S. E., 581  
 Mills, J., 661  
 Monath, T. P., 165  
 Monteiro, M., 386  
 Morales-Doria, M., S131  
 Moreno, S., 1201  
 Morrissey, A. B., 799  
 Mousa, A. R. M., 531  
 Muhtaseb, S. A., 531  
 Murphy, T. F., 1  
 Musher, D. M., 1192  
 Mylotte, J. M., 891  
 Negroni, R., S47  
 Nelkin, D., 980  
 Nelson, C. L., 613  
 Nelson, K. E., 908  
 Neu, H. C., 220, 621, 1001  
 Neugebauer, E., S585  
 Newman, K. A., 206  
 Nightingale, C. H., S160  
 Nilsson-Ehle, I., 250  
 Northoff, H., S599, S602  
 Nowotny, A., S503  
 Nuijten, S. T. M., S119  
 O'Brien, R. J., 519  
 O'Brien, T. F., S244  
 O'Connor, R. W., S232  
 Ofek, I., S351  
 Olszewski, W., 713  
 Olyhoek, T., 665  
 Overturf, G. D., S168, 719  
 Padian, N. S., 947  
 Palacio Hernanz, A. del, S121, S139  
 Palmieri, O., S47  
 Panconesi, E., S109  
 Pankey, G. A., 619

- Parras, F., 810  
 Parsonnet, J., S482  
 Pastan, I., S644  
 Pathmanathan, R., 1026  
 Patiño, M. M., S51  
 Paulsen, H. J., 1179  
 Peacock, J. E., Jr., 88  
 Perez, F., 1038  
 Pérez, G., 386  
 Petersdorf, R. G., 227  
 Peterson, P. K., 604, 1127  
 Phair, J. P., 369  
 Phillips, P., S87  
 Pitlik, S. D., 54, 1102  
 Pizzo, P. A., 214  
 Plummer, F. A., 846  
 Plumridge, R., S286  
 Pottage, J. C., Jr., 329  
 Proctor, R. A., S317, S335, S412  
 Putlitz, G., S437  
 Quie, P. G., 189  
 Quintanilla, A., 369  
 Quintiliani, R., S160  
 Raffin, T. A., 1163  
 Raimondi, A., S134  
 Ramos, F. M., S121  
 Rapp, S. S580  
 Reich, C. V., 590  
 Reid, G., 470  
 Reiner, S. L., 581  
 Reller, L. B., 961  
 Remington, J. S., S153, 754, 775, 1055  
 Restrepo, A., S51  
 Reynoso, S., S64  
 Ribí, E., S512  
 Richter, J. E., 88  
 Rietschel, E. T., S527  
 Rimland, D., 1120  
 Rinaldi, M. G., 1006  
 Robins-Browne, R. M., 28  
 Robledo, J., S51  
 Rocha, H., S261  
 Rodríguez-Créixems, M., 810  
 Rosenfeld, J. B., 1102  
 Rosenstreich, D. L., S594  
 Rubin, L. G., 488  
 Sacks, T., S270  
 Sadoff, J. C., S644  
 Saito, T., 494  
 Saltzman, R. L., 1127  
 Salzman, G., 795  
 Sánchez-Sousa, A., 1201  
 Sandberg, A. L., S467  
 Sanz, F. S., S139  
 Saravolatz, L. D., S218  
 Saúl, A., S100  
 Sawyer, L. A., 935  
 Schade, U., S527  
 Schaffner, A., S620  
 Schaffner, T., S620  
 Scheckler, W. E., S270  
 Scheld, W. M., S400  
 Schimpff, S. C., 206  
 Schleupner, C. J., 925  
 Schuermans, V., S146  
 Schuller, J. L., S119  
 Scrimshaw, N. S., 428  
 Seeger, W., S570  
 Seydel, U., S527  
 Shekhar, K. C., 1026  
 Schenep, J. L., S639  
 Shibl, A. M., 704  
 Shurin, P. A., 16  
 Sidorczyk, Z., S527  
 Simon, H. J., S261, 851  
 Simpson, W. A., S351  
 Singer, C., 134  
 Sisson, P. R., 650  
 Small, P., S450  
 Smego, R. A., Jr., 855  
 Smith, M. B., 1006  
 Smith, P. W., 662  
 Snider, D. E., Jr., 519  
 Snyderman, R., S562  
 Sobel, J. D., 470  
 Soe, G. B., 719  
 Solem, L., S512  
 Solomon, S. L., 1065  
 Somma, S., 386  
 Somma-Moreira, R. E., 386  
 Sory, M.-P., 64  
 Soumerai, S. B., S286  
 Southern, P. M., Jr., 124  
 Spagnuolo, P. J., 140  
 Spector, S. A., 743  
 Sperber, S. J., 925  
 Spooner, J. A., 891  
 Spritz, N., 660  
 Stamey, T. A., S195  
 Steele, J. H., 447  
 Stein, D. S., 908  
 Stephens, D. S., 1120  
 Stevens, D. A., S77  
 Stoops, K., S146  
 Suchil, P., S64  
 Tacken, A., S527  
 Takaoka, Y., 494  
 Tauber, W. B., 110  
 Tauxe, R. V., 511  
 Taylor, D. N., 841  
 Taylor, S. A., 693  
 Teixeira, J., 376  
 Thamlikitkul, V., S270  
 Thisyakorn, U., 841  
 Tiraboschi, I. N., S47  
 Todd, J. R., IV, 562  
 Tomai, M., S512  
 Tricot, G., S94  
 Tupasi, T., S270  
 Tyrrell, D. A. J., 243  
 Umezawa, H., 147  
 Urbaschek, B., S431, S607, S616  
 Urbaschek, R., S431, S607, S616  
 Van Cauteren, H., S43  
 Van Cutsem, J., S15  
 Van de Ven, M.-A., S33  
 Van Gerven, F., S15  
 Van Hare, G. F., 16  
 van Saene, H. K. F., 295  
 Vande Pitte, J., S94  
 Vazquez, F., 1038  
 Verghese, A., 884, 1140, 1186  
 Verghese, M. W., S562  
 Verhoeve, L., S104  
 Vernon, A. A., 511  
 Vicente, S. D., S121  
 Villalba, I., S134  
 Voiriot, P., 376  
 Vollaard, E. J., 295  
 von Reyn, C. F., 227  
 Wachter, R. M., 1163  
 Wagner, W., S456  
 Walker, D. H., 823  
 Wallace, C. K., S231, S313  
 Walling, D. M., 1013  
 Warren, H. S., S630  
 Washington, J. A., II, 275  
 Wauters, G., 64  
 Weisman, I., S87  
 West, B. C., 562  
 Wheeler, R. R., 88  
 Wiese, K., 799  
 Wiest, P. M., 799  
 Wilfert, C. M., 334  
 Williams, J., 369  
 Willingham, M. C., S644  
 Winn, R. E., 1006  
 Witt, W., 799  
 Wofsy, C., 661, S184  
 Wolinsky, E., 140  
 Wolpl, A., S599  
 Woods, D. E., S386  
 Woods, G. L., 275  
 Wykoff, R. F., 433  
 Wyler, D. J., S391  
 Wyngaarden, J. B., S443  
 Yeung, M. K., S467  
 Yoder, E. L., 382  
 Yost, S. L., S594  
 Young, L. S., S177  
 Yu, S.-R., 823  
 Zackon, H. M., 578  
 Zähringer, U., S527  
 Zinsser, H., 636  
 Zupan, A., S44, S490

# Subject Index

- Abscess, spinal epidural, 265
- Acanthamoeba, waterborne, infections, 54
- Achromobacter xylosoxidans* bacteremia, antimicrobial agents against, 1001
- Acquired immunodeficiency syndrome. *See* AIDS
- Acrylic cement, antibiotic-impregnated, in joint-replacement surgery, 613
- Actinomyces
  - adherence to epithelial cells, PMNs, S467
  - CNS infection due to, 855
  - coaggregation with *S. sanguis*, S467
  - fimbriae
    - cloning of type 1 and type 2, S467
    - vaccination, S647
- Actinomycetoma, differential diagnosis, 581
- Actinomycosis
  - of the CNS, 855
  - primary infection of an extremity, 581
- Adherence, bacterial
  - Actinomyces, to epithelial cells, PMNs, S467
  - of *E. coli* to intestinal mucosa, 28
  - role of teichoic acid and fibronectin, S341
  - staphylococcal toxin and phagocytosis, effect of antibiotics, 704
  - S. aureus*, S335
  - streptococcal, to human cells, S475
  - in urinary tract, 470
- Adherence, viral, actinomyces to epithelial cells, PMNS, S467
- Adjuvants, characterization of nontoxic, S512
- Adult respiratory distress syndrome due to falciparum malaria, 134
- Aeromonas hydrophila*
  - aerolysin, S456
  - waterborne, infections, 54
- Agammaglobulinemia, complicated by enteroviral meningoencephalitis, 335
- Aging (*see also* Elderly)
  - immune function, 1127
  - restoration of immune response, S512
- AIDS (*see also* HIV infections; *specific infections*)
  - alternaria infection, treatment with amphotericin, 799
  - animal models for, 438
  - cultural practices relating to in Africa, 1109
  - discrimination and perception of risk, 980
  - education and behavior change, 980
  - health care for patients, 980
  - heterosexual transmission, 987
  - intensive care, ethical dilemmas, 1163
  - media communication about, 987
  - M. avium* complex infection, treatment of with rifabutin, 519
  - P. carinii* infection, treatment with trimethoprim-sulfamethoxazole, S184
  - pre-AIDS era, probable cases, 1102
  - public policy, 980
  - and salmonellosis, 925
  - social science research, 980
- Airborne pathogens, infections in immunocompromised patients, 206
- Alcoholism, susceptibility to DF-2 infection, 884
- Alternaria alternata* infection in AIDS, 799
- Aminoglycoside antibiotics
  - bacterial resistance worldwide, S224
  - mechanism of resistance to, 147
- Amphotericin B
  - in evolution of antifungal agents, S4
  - for alternaria infection in AIDS, 799
  - short-course and combination therapy, 403
- Anaerobiospirillum succiniciproducens* bacteremia, 737
- Anemia, hemolytic and trimethoprim-sulfamethoxazole treatment in glucose-6-phosphate dehydrogenase-deficient patients, S218
- Animal models
  - of diarrhea due to *E. coli*, 28
  - of infection due to *Y. enterocolitica*, 67
  - of yellow fever, 165
- Ansamycin LM427. *See* Rifabutin
- Antibiotic(s) (*see also* Antimicrobial agents; *names of specific agents*)
  - aminoglycoside, 147
  - availability and use at the national level worldwide, estimates, S232
  - compassionate therapy, problems and benefits, S232
  - economic consequences of therapy, S297
  - gut decontamination, selective, 295
  - information and education as determinants of use, S286
  - patterns and changes of resistance worldwide, S224
  - pharmacokinetics
    - in the elderly, 250
    - of tissue penetration, 713
  - policies and restrictions on use [editorial], S851
  - regulations of use worldwide, S261
  - resistance of *B. catarrhalis*, 16
  - resistance, patterns and changes worldwide, S244
  - strategies for improving use, S286
  - subinhibitory concentrations, influence on staphylococci, 704
  - subtherapeutic doses, in animal feeds, 447
  - tissue penetration, 713
  - use in developing countries, S270
  - use and resistance worldwide, symposium, S231-316
- Antifungal agents (*see also* *specific agents*)
  - amphotericin B, short-course and combination therapy, 403
  - evolution of, S4
  - itraconazole, in aspergillosis, sporotrichosis, and cryptococcosis, in animal models, S15
  - systemic, antimicrobial spectrum, S4
- Antifungal testing, mycosis due to *C. lusitanae*, 1008
- Antigen(s)
  - detection in diagnosis of aspergillosis and candidiasis, 398
  - polysaccharide O and K, of *E. coli*, S517
- Antimicrobial agents, Berger (1986;8:756-9), erratum, 429
- Antimicrobial resistance (*see also* under Antibiotics; Resistance)
  - health and economic impacts, 1065
  - due to antibiotic supplementation of feed, 447
- Antitumor drugs, 147
- Arachidonic acid, metabolites as mediators of endotoxin effects, S553
- Armillos, as a source of *M. leprae*, 562
- Armillifer armillatus* infection, 1087
- Aspergilloma, renal, due to *A. flavus*, 790

- Aspergillosis**  
antigen detection for diagnosis, 398  
treatment with itraconazole, S71  
**Aspergillus** infection, prophylaxis with itraconazole in neutropenic patients, S94  
*Aspergillus flavus*, renal aspergilloma, 790  
*Aspergillus fumigatus*  
effects of glucocorticoids on immunity to, S620  
ultrastructure after treatment with itraconazole, S33  
*Bacillus cereus* endophthalmitis, mechanism of pathogenicity, 110  
**Bacteremia**  
due to *A. succiniciproducens*, 737  
due to *A. xylosoxidans*, 1001  
anaerobic, in a general hospital in Spain, 1038  
due to methicillin-resistant *S. aureus*, 891  
osteoarthropathy-associated, 376  
due to *Salmonella*, in AIDS patients, 925  
**Bacterial adherence**. See **Adherence**  
**Bacterial infections** (see also *specific infections*)  
intracellular, role of T cells, S650  
from multiple of a single organism, 488  
**Bacterial invasion**, molecular biology, S450  
**Bacterial lipopolysaccharides**. See **Lipopolysaccharides**  
**Bacterial pathogenesis** symposium, S431-S659  
**Bacteriophage Mu**, 357  
*Bacteroides fragilis* meningitis, 783  
 $\beta$ -lactamase of *B. catarrhalis*, 16  
Biomedical research, National Institutes of Health and, S443  
**Bleomycins**, structure and functions of, 147  
**Bone**, susceptibility to infection, 613  
*Branhamella catarrhalis*  
otitis media, 16  
respiratory infection, 1140  
**Bronchitis**, due to *B. catarrhalis*, 1140  
*Brucella melitensis*, in brucellosis, 531  
*Brucella* species meningitis, neurobrucellosis, 810  
Brucellosis, osteoarticular complication, 531  
Brodzinski's sign of meningeal irritation, 1140  
**Candida albicans**  
binding to fibronectin, role in pathogenesis, S400  
ultrastructure after treatment with itraconazole, S33  
vaginitis due to, treatment with itraconazole, S143  
*Candida lusitanae* sepsis, antifungal testing, 1006  
*Candida neoformans*, ultrastructure of after treatment with itraconazole, S33  
**Candidosis**  
antigen detection for diagnosis, 398  
chronic oral, treated with itraconazole, S114  
vaginal  
acute, comparative trial of three regimens of itraconazole, S139  
due to *C. albicans*, S143  
effect of treatment of sexual partner with itraconazole, S143  
**CAPD**, 604  
**Case report(s)**  
*A. xylosoxidans* bacteremia, 1001  
actinomycosis of the CNS, 855  
alternaria infection in AIDS patient, 799  
disseminated infection due to *T. beigeli*, 1013  
dysgonic fermenter 2 septicemia, 884  
endocarditis due to nutritionally deficient streptococci, 908  
*K. indologenes* endocarditis, 787  
meningitis, mixed bacterial, 693  
meningitis, neurobrucellosis, due to *Brucella* species, 810  
*M. furfur* fungemia complicating hyperalimentation, 743  
*M. szulgai* infection, 1120  
mycoses due to *C. lusitanae*, 1006  
neurocysticercosis in United States, 961  
prosthetic valve endocarditis due to small-colony staphylococcal variants, 1168  
pulmonary sporotrichosis, 795  
respiratory infection caused by *B. catarrhalis*, 1140  
salmonellosis during HIV infection, 925  
schistosomiasis in Malaysia, 1026  
*S. aureus* bacteremia, 891  
ureteral obstruction due to aspergilloma, 790  
Cefoperazone, for treatment of typhoid fever, 719  
Cefotaxime, for treatment of typhoid fever, 719  
Ceftriaxone, for treatment of typhoid fever, 719  
Cell surfaces, interaction with fibronectin, S322  
**Cephalosporins**  
bacterial resistance worldwide, S224  
for treatment of typhoid fever, 719  
**Cerebrospinal fluid shunts**, infections, S95  
**Cesarean section**, prophylaxis with trimethoprim-sulfamethoxazole, S211  
**Chloramphenicol**, bacterial resistance worldwide, S244  
**Cholera**, enterotoxins,  $G_M$ -ganglioside receptors binding sites, monoclonal antibodies to, S490, S44  
*Chromobacterium violaceum*, waterborne, infections, 54  
**Chromomycoses**, treatment with itraconazole, preliminary experience in Mexico, S64  
*Cladosporium carrionii* infection treated with itraconazole, S57  
**Clindamycin**, bacterial resistance worldwide, S244  
**CNS infection**  
due to *Actinomyces* species, 855  
due to *S. schenckii*, 369  
**Coccidioidomycoses**, treatment with itraconazole, experience in Mexico, S64  
**Colonization**, bacterial from single organism, 488  
**Colony-stimulating factor** induced by interleukin-1, tumor necrosis factor, S607  
**Compassionate therapy**, problems and benefits, 1095  
**Complement**  
C3 and C4, 97  
C3 thiolester of, in infection, 97  
in lysis of gram-negative bacteria, S537  
and septic lung, S570  
**Compromised hosts**. See **Immunocompromised patients**  
**Continuous ambulatory peritoneal dialysis**, peritonitis in, 604  
**Controversies**, diagnosis and management of infectious diseases  
fungal infections, 392-420  
immunology, 189-221  
implanted devices, 595-624  
**Cost-effectiveness** of education regarding antibiotic use, S286  
*Coxiella burnetii*, in Q fever, 935  
**Cryptosporidiosis**, Soave and Armstrong (1986;8:1012-23), erratum, 663  
**Cytolysins**, bacterial, aerolysin, hemolysin, listeriolysin, molecular analysis, S456



- Decontamination of the gut, selective, 295
- Dermatophytoses, treatment with itraconazole, S104, S109, S114
- Developing countries, antibiotic use patterns, S270
- Diabetes mellitus in mice, encephalomyocarditis, virus-induced, 917
- Diagnosis, rapid, in candidiasis and aspergillosis, 398
- Diarrhea, infantile due to *E. coli*, 28
- Dog bites, DF-2 infection, 884
- Doyle, A. Conan, Sherlock Holmes, "The Adventure of the Dying Detective," 222
- Drug abuse, iv, and *T. capitatum* fungemia [correspondence], 1202
- Dysgonic fermenter 2 septicemia (DF-2), 884
- Echoviruses, causing meningoencephalitis in agammaglobulinemic patients, 334
- Economic evaluations, of antibiotic use and resistance worldwide, S297, 1065
- Education of physicians as determinant of antibiotic use, S286
- Eicosanoids in septic lung, S570
- Elderly (see also Aging)
- immune function, 1127
  - pharmacokinetics of antibiotics, 250
- Encapsulated bacteria, vaccines, 176
- Encephalitis, due to varicella-zoster virus, 1020
- Encephalomyocarditis virus-induced diabetes mellitus in mice, 917
- Endocarditis
- infective
    - pathogenesis, S360
    - role of fibronectin, S360
  - due to *K. indologenes*, 787
  - due to nutritionally deficient streptococci, therapeutic dilemmas, 908
  - due to *S. aureus*, 891
  - prosthetic valve, due to small-colony staphylococcal variants, 1168
- Endomyometritis, prophylaxis with trimethoprim-sulfamethoxazole, S211
- Endophthalmitis, posttraumatic, due to *B. cereus*, 110
- Endotoxemia, role of acute-phase response, treatment of, S630
- Endotoxin(s)
- antibodies to core glycolipid, S639
  - arachidonic acid and, S553
  - beneficial effects, interleukin-1, tumor necrosis factor, as mediators, S607
  - host defense, role in response, S616
  - Kupffer cells, effect on response, S616
  - molecular aspects of action, S503
  - nontoxic derivative, S512
  - shock
    - histamine, in development of, S585
    - leukotrienes, role, S580
    - lipid mediators in, S580
    - pathogenesis of, S580, S585
    - treatment of, S585
  - structure and function, S503
  - superoxide radicals and, S553
  - tumor necrosis factor as mediator of, S602
- Enteric bacteria, invasion of epithelial cell by, S450
- Enterotoxin(s)
- chimeras, S44, S490
  - cholera family, epitopes, S44, S490
  - E. coli*, monoclonal antibodies and epitopes, S44, S490
  - of *Y. enterocolitica*, 64
- Enteroviruses, causing meningoencephalitis in agammaglobulinemic patients, 334
- Enzyme inhibitors, low-molecular-weight, 147
- Epidemiology of nosocomial gram-negative bacillary infections, 1079
- Epidural abscess, spinal, nontuberculous, 265
- Epithelial cell, invasion by enteric bacteria, S450
- Errata
- Berger (1986;8:756-9), 429
  - Soave and Armstrong (1986;8:1012-23), 665
  - Brooks et al. (1987; 9:775-82), 1055
- Erythromycin, bacterial resistance worldwide, S244
- Escherichia coli*
- antibodies to core glycolipid, S639
  - antigens, capsular and cell wall polysaccharides, S517
  - enteropathogenic, 28
  - enterotoxins, monoclonal antibodies and epitopes, S44, S490
  - hemolysin, S456
  - J5, antiserum to for passive immunotherapy, 194
- Esophagitis, infectious, esophagoscopy in diagnosis, 88
- Fellowship training, infectious disease, 388
- Fever, unexplained, in neutropenic patients, 214
- Fibronectin
- in bacterial adherence to epithelial cells, S341
  - binding to *Candida*, role in pathogenesis, S400
  - binding to *S. pyogenes*, S351
  - in infective endocarditis, S360
  - interaction with bacteria, effect of penicillin on, S475
  - interaction with cell surfaces, S322
  - interaction with viruses, S404
  - overview, S317
  - in pathogenesis of gram-negative pneumonia, S388
  - in pathogenesis of syphilis, S372
  - in parasitic diseases, S391
  - and phagocyte function, S412
  - plasma levels in sepsis, S420
  - S. aureus* receptor, S335
  - symposium, S317-S430
  - therapy in critical illness, sepsis, S420
- Fimbriae of enteropathogenic *E. coli*, 28
- Flucytosine, in combination with amphotericin B, 403
- Foodborne pathogens, infections due to immunocompromised patients, 206
- Fungal infection
- antifungal susceptibility testing, 392
  - diagnosis and management, summary, 417
  - prevention of in immunocompromised patients, 408
  - short-course and combination therapy for systemic infection, 403
- Fungemia
- due to *M. furfur*, and hyperalimentation, 743
  - due to *T. capitatum* [correspondence], 1202
- Ganglioside, GM<sub>1</sub>, receptors for cholera-related enterotoxins, S44, S490
- Gangrene, due to *S. pyogenes*, 382
- Gastrointestinal malignancy mimicked by esophageal tuberculosis, 140

- Gentamicin, resistance in nosocomial Enterobacteriaceae, 1079  
Geriatric population. *See* Elderly; Aging  
Glucocorticoids  
    effects on immunity to *A. fumigatus*, *L. monocytogenes*, *N. asteroides*, S620  
    macrophages, effects on antimicrobial activity, S620  
Glucose-6-phosphate dehydrogenase deficiency, use of trimethoprim-sulfamethoxazole, S218  
Graft-related infection, osteoarthritis, 376  
Gram-negative bacillary pneumonia, pathogenesis, S386  
Gram-negative bacteria  
    antibodies to core glycolipid, S639  
    infections due to motile anaerobic, 1150  
    lysis, function of antibody and complement, S537  
Granulocytopenia  
    treatment with granulocyte transfusions, 189  
    unexplained fever in patients, 214  
Guanine nucleotide regulatory proteins and leukocyte activation, phospholipase C, S562  
Gut decontamination, selective, 295  
  
*Haemophilus influenzae*  
    nontypable, outer membrane proteins, respiratory infections due to, and surface antigens of, 1  
    vaccines against, 176  
Halzoun syndrome, 1087  
Heidelberg University history, S437, S439  
Hemolysin of *E. coli*, S456  
Hemostatic system, influence of leukocytes, S546  
Herpes simplex virus, causing hepatitis, 329  
Histamine in endotoxin shock, receptor antagonists and treatment of, S585  
Histoplasmosis  
    due to *H. duboisii*, treatment with itraconazole, S71  
    treatment, S47  
HIV infection (*see also* AIDS)  
    in chimpanzees, 438  
    and salmonellosis, 925  
Hospital-acquired infections. *See* Nosocomial infection(s)  
Hospital hotel services as risk factors for infections in immunocompromised patients, 206  
Host defense, effect of endotoxin, role of Kupffer cells, S616  
Human immunodeficiency virus. *See* HIV infection  
  
Immune response, enhancement by a nontoxic adjuvant, restoration of in aging, S512  
Immunity in the elderly, 1127  
Immunization, with pneumococcal polysaccharides, 494  
Immunocompromised patients  
    infectious esophagitis in, 88  
    management of infection in, 220  
    mycoses, prevention, 408  
    risk factors for infections, 206  
    treatment with trimethoprim-sulfamethoxazole, S177  
Immunodeficiency, in elderly, 1127  
Immunoglobulin  
    intravenous, 194  
    in enteroviral meningoencephalitis, 334  
Immunomodifiers, low-molecular-weight, 147  
Immunotherapy, passive, for bacterial infections, 194  
Implanted devices, infections, 619  
  
Infectious disease rounds  
    fever and rash in pregnancy, measles, 1175  
    trichinosis, 804  
    varicella-zoster virus encephalitis, 1020  
Infectious disease specialists, training of, 226 [correspondence], 388 [editorial]  
Interferon(s)  
    early research, 243  
    inducing particle phenotype, 917  
Interleukin-1  
    human urine-derived inhibitors of, S594  
    inducer of colony-stimulating factor, S609  
    mediator of endotoxin-induced beneficial effects, S607  
    uromodulin and, S594  
Itraconazole  
    antifungal activity in vitro, S15, S77  
    for aspergillosis, S71  
    for deep mycoses, S57, S64  
    for deep and disseminated mycoses, animal models, S15  
    for dermatophytoses, S104, S109  
    for histoplasmosis, S47  
    vs. ketoconazole for antifungal prophylaxis in neutropenic patients, S94  
    kinetics, pharmacologic studies, S43  
    for mycoses  
        human, review of clinical experience, S146  
        progressive, S77  
        superficial, S100  
        systemic, S71  
        vaginal, S139  
    for paracoccidioidomycosis, S47, S51  
    for pityriasis versicolor, S109, S128, S131  
    ultrastructural changes in *M. furfur* produced during treatment, S134  
    summary of symposium, S1  
    symposium, S1-S152  
    for tinea corporis, S119  
    toxicology, S77  
  
Joint replacement, total, prevention of infection, 613  
  
Kaposi's sarcoma in the pre-AIDS era, 1102  
Kernig's sign of meningeal irritation, 1187  
Ketoconazole  
    vs. itraconazole for antifungal prophylaxis, S94  
    for pulmonary sporotrichosis, 795  
*Kingella indologenes*, endocarditis, case report, 787  
Kupffer cells, role in host defense, effect on endotoxin, S616  
  
*Legionella*, waterborne, infections, 54  
*Leishmania*, role of fibronectin in disease, S391  
Leishmaniasis, trial of itraconazole for, S57  
Lentivirus infection in animals, model for AIDS, 438  
Leprosy  
    cause of transmission, theory of pathogenesis, S90  
    nonhuman environment, sources of, S62  
Leptospira, waterborne, infections, 54  
Leukocyte(s)  
    activation by chemoattractants, guanine nucleotide regulatory proteins in, S562

- hemostatic system and, proteases, effects on clotting factors and platelets, S562
  - platelet activating factor, origin of, S546
  - Leukotrienes**
    - cysteinyl, LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>, S580
    - elimination, role of liver, S580
    - role in endotoxin shock, S580
  - Linguatula serrata* infection, 1087
  - Lipid A**
    - bacterial, chemical structure and biologic activity, S527
    - nontoxic monophosphoryl derivative, S512
    - synthetic, chemical structure and biologic activity, S527
  - Lipid mediators in endotoxin shock, S580
  - Lipopolysaccharide(s)
    - beneficial effects, S607
    - core glycolipid of, antibodies to, S639
      - in passive immunotherapy, 194
    - detection in serum, S599
    - interleukin-1, induction by, S599
    - neutralization of, S630
    - radiation sickness and, S607
    - and resistance to infections, S607
    - serum, interactions with, S599
    - and tumor necrosis, S607
  - Listeria monocytogenes*
    - effects of glucocorticoids on immunity to, S620
    - listeriolysin, S456
    - rhombencephalitis due to, 130
    - and T cells, S650
  - Listeriolysin, of *L. monocytogenes*, S456
  - Listeriosis, murine model, T cell role in defense, S650
  - Liver, in elimination of leukotrienes, S580
  - Lymph, antibiotics in human peripheral, 713
  - Lymphadenopathy
    - diagnosis, serology, 775, 1055
    - due to *T. gondii*, clinical spectrum, 754
  - $\alpha_2$ -Macroglobulin, thiolester bond in, 97
  - Macrophages**
    - effects of glucocorticoids on antimicrobial activity, S620
    - tissue thromboplastin, source of, S546
  - Madurella grisea* infections, treatment with itraconazole, S57
  - Malaria, falciparum, pulmonary edema and fibrosis, 134
  - Malassezia furfur*
    - fungemia, complicating hyperalimentation, 743
    - ultrastructural changes produced by itraconazole, S134
  - Media communication about AIDS, 987
  - Meningitis**
    - diagnosis, 1187
    - due to *B. fragilis*, 783
    - due to *Brucella* species, chronic, 810
    - due to *N. meningitidis* serogroup A, epidemiology, 665
    - mixed bacterial, 665
    - physical signs, 1187
  - Meningoencephalitis, due to enteroviruses in agammaglobulinemic patients, 334
  - Metronidazole, for treatment of *B. fragilis* meningitis, 783
  - Microbiologic testing, automation of, 655
  - Molecular mechanisms, for transposition of drug-resistance genes, 357
  - Monoclonal antibodies
    - to cholera and related enterotoxins, 544, S490
    - to *E. coli* enterotoxins, 544, S490
  - Monocytes**
    - effect of fibronectin, S412
    - as source of tissue thromboplastin, S546
  - Mycobacteria**
    - atypical, 275
    - nontuberculous infection, due to *M. szulgai*, 578
    - rarely pathogenic types, 286
    - waterborne, infections, 54
  - Mycobacterium avium*-complex infection, treatment with rifabutin, 519
  - Mycobacterium avium*-*Mycobacterium intracellulare* complex, microbiologic and clinical aspects, 275
  - Mycobacterium fortuitum*-*Mycobacterium chelonae* complex, 281
  - Mycobacterium haemophilum*, 275
  - Mycobacterium kansasii*, 280
  - Mycobacterium leprae*, human infection, environmental sources of, 562
  - Mycobacterium mageritense*, 283
  - Mycobacterium marinum*, 275
  - Mycobacterium scrofulaceum*, 279
  - Mycobacterium simiae*, 275
  - Mycobacterium szulgai*, infection, 578, 1120
  - Mycobacterium tuberculosis*, esophageal disease due to, 140
  - Mycobacterium ulcerans*, 275
  - Mycobacterium xenopi*, 282
- Mycoses**
  - due to *C. lusitanae*, antifungal testing, 1006
  - future trends in treatment of, S4
  - in immunocompromised patients, prevention, 408
  - itraconazole treatment
    - of deep and disseminated S57, S64
    - animal models, S15
    - human, review of clinical experience, S146
    - superficial, in animal models, S15
    - systemic, S87
- Myositis, due to *S. pyogenes*, 382
- Naegleria*, waterborne, infections, 54
- National Institutes of Health (NIH)
  - biotechnology, role in, S443
  - funding, S443
  - history, S443
  - Task Force reports on antibiotic use and resistance, S231-S316
- Native American, pre-Columbian, and tuberculosis, 1180
- Neisseria gonorrhoeae*, immunity, hypothesis, 846
- Neisseria meningitidis*
  - serogroup A, clonal analysis, 665
  - vaccines against, 176
- Neurocysticercosis, diagnosis by computed tomography, epidemiology, serologic diagnosis, medical and surgical treatment, 961
- Neutropenia, management, 214
- Neutropenic patients, antifungal prophylaxis with itraconazole, S94
- Nocardia asteroides*
  - glucocorticoids, effects on immunity to, S620
  - meningitis due to, in absence of abscess, 228 [correspondence], 662



- Nocardiosis, differential diagnosis of primary cutaneous infection, 581
- Nosocomial infection(s)  
   due to *P. aeruginosa* and Enterobacteriaceae, 1079  
   treatment with trimethoprim-sulfamethoxazole, S160  
   with rabies virus, 511
- Nystatin, in evolution of antifungal agents, S4
- Opsonic activity, role of fibronectin, S404
- Osteoarthritis, due to infected aortic graft, 376
- Otitis media, due to *B. catarrhalis*, 16
- Paracoccidioides brasiliensis*  
   infections, treatment with itraconazole, S57  
   ultrastructure after treatment with itraconazole, S33
- Paracoccidioidomycosis, treatment with itraconazole, S47, S51
- Parasitic diseases, role of fibronectin, S391
- Parasitosis, delusions of, 433
- Pathogenesis, bacterial  
   of gram-negative bacillary pneumonia, S386  
   mechanism of, 488  
   symposium, S431-S659
- Pediatric infections, iv treatment with trimethoprim-sulfamethoxazole, S168
- Penicillin(s)  
   bacterial resistance worldwide, S244  
   effect on fibronectin-bacteria interaction, streptococcal adherence, S475
- Pentastomiasis, 1087
- Peritonitis, in patients undergoing continuous ambulatory peritoneal dialysis, 604
- Pertussis, vaccine efficacy, 866
- Phagocytes, role of fibronectin in response, S412
- Phagocytosis, role of C3 thiolester in, 97
- Pharmacokinetics  
   of antibiotics in the elderly, 250  
   of itraconazole, S43
- Phospholipase C, guanine nucleotide regulatory proteins and, S562
- Picornavirus, virulence in mice, 917
- Pityriasis versicolor, treatment with itraconazole, S109, S121, S128, S131  
   vs. selenium sulfide, S121  
   ultrastructural changes in *M. furfur*, S134
- Pityrosporum orale*, ultrastructure of, after treatment with itraconazole, S33
- Plague, murder by, 222
- Plasmids, virulence of *Y. enterocolitica*, 64
- Plasmid-mediated gentamicin resistance, 1079
- Plasmodium falciparum*, mechanism of infection, 134
- Platelet activating factor, of leukocyte origin, S546
- Pneumococci, immunization with polysaccharides of, 494
- Pneumocystis carinii* pneumonia  
   in patients with AIDS, 660  
   in pre-AIDS era, 1102  
   treatment with trimethoprim-sulfamethoxazole, S168
- Pneumonia  
   due to *B. catarrhalis*, 1140  
   gram-negative bacillary, pathogenesis, S386
- Polymicrobial infection, meningitis, 693
- Polysaccharides, pneumococcal, maternal immunization with and neonatal responses to, 494
- Prophylaxis  
   with trimethoprim-sulfamethoxazole, in abdominal, pelvic, and prostatic surgery, S211  
   antibiotic, economic consequences, S297
- Prototheca*, waterborne, infections, 54
- Pseudomonas*, waterborne, infections, 54
- Pseudomonas aeruginosa*  
   antibiotic resistance, 1079  
   cytotoxin in septic lung, S570  
   infections due to, passive immunotherapy, 194  
   toxin A, use in vaccines and immunotoxins, S644
- Pseudomonas testosteroni* infections, 124
- Psychosis, parasitosis and, 433
- Pulmonary edema, noncardiogenic, in falciparum malaria, 134
- Pulmonary infection, *M. szulgai*, 578
- Q fever  
   acute and chronic disease, 935  
   in China, 823  
   in endocarditis, 935  
   epidemiology, treatment and control, 935  
   in Uruguay, 386
- R factors, transfer of resistance by, influence of antibiotic-enriched feeds, 447
- Rabies virus, human-to-human transfer, from corneal transplantation, nosocomial, 511
- Renal colic, due to obstructing aspergilloma, 790
- Resistance, antimicrobial  
   genes, bacterial, 398  
   transposition, 357  
   health and economic impacts worldwide, 1065  
   patterns and changes worldwide, S244
- Retroviruses, in animal models of AIDS, 438
- Rhombencephalitis, due to *L. monocytogenes*, 130
- Rickettsial disease, in China, epidemiology, 823
- Rifabutin for treatment of mycobacterial disease, 519
- Rifampin  
   combination with amphotericin B, 403  
   in treatment of brucellosis, 531
- Rotavirus, infection in adults, epidemiology, waterborne outbreaks, 461
- Salmonella*, antibiotic-resistant, 1065
- Salmonella paratyphi* A, vaccination in Thailand, 841
- Salmonella typhi*, vaccination in Thailand, 841
- Salmonellosis  
   in AIDS patients, 925  
   influence of antibiotic supplementation of animal feeds, 447  
   systemic, treatment with cephalosporins, 719
- Schistosoma*, waterborne, infections, 54
- Schistosoma japonicum* infection in Malaysia, 1026
- Schistosomiasis  
   in Malaysia, 1026  
   role of fibronectin, S391
- Selective decontamination of the gut, 295
- Semiautomated susceptibility systems [correspondence], 1202

- Sepsis  
 fibronectin therapy, S420  
 due to gram-negative bacteria, treatment with granulocytes, 189
- Septic lung  
 complement system and, S570  
 eicosanoids in, S570  
*P. aeruginosa* cytotoxin in, S570
- S. aureus*  $\alpha$ -toxin in, S570
- Serum protein binding, 713
- Shigella*, virulence determinants, S450
- Shock, endotoxin. See Endotoxin, shock
- Simian immunodeficiency virus, in animal model of AIDS, 438
- Smallpox, vaccination in United States, 1044
- Smith, Theobald  
 biographical memoir of, 636  
 a unique tribute to, 625
- Spinal epidural abscess, nontuberculous, 265
- Splenectomy, susceptibility of DF-2 infection, 884
- Sporothrix schenckii*  
 infection due to, treated with itraconazole, S57  
 pulmonary disease, treatment with ketoconazole, 795
- Sporotrichosis  
 itraconazole for, preliminary experience in Mexico, S64  
 pulmonary, ketoconazole for, 795  
 in renal transplant recipient, 369
- Staphylococci  
 prosthetic valve endocarditis due to small-colony variants, 1168  
 virulence factor, influence of antibiotics, 704
- Staphylococcus aureus*  
 $\alpha$ -toxin in, and septic lung, S570  
 adherence to epithelial cells, role of teichoic acid and fibronectin, S341  
 bacteremia, 891  
 in cerebrospinal fluid shunt infections, 595  
 fibronectin receptor, adherence, S335  
 methicillin-resistant, 1065
- Staphylococcus epidermidis*  
 in cerebrospinal fluid shunt infections, 595  
 peritonitis due to, continuous ambulatory peritoneal dialysis, 604
- Streptococci  
 adherence, to human cells, effect of penicillin, S475  
 binding of fibronectin, S351  
 nutritionally deficient, in endocarditis, 908  
 pneumonia, vaccines, 176
- Streptococcus pneumoniae*, vaccines against, 176
- Streptococcus pyogenes*  
 binding of fibronectin, S357  
 causing gangrene, myositis, 382
- Streptococcus sanguis*, coaggregation, with actinomyces, S467
- Streptomycin, in treatment of brucellosis, 531
- Sulfonamides, bacterial resistance, worldwide, S244
- Superoxide radicals, mediators of endotoxin effects, S553
- Susceptibility testing  
 antifungal, 392  
 semiautomated [correspondence], 1202
- Synergism, of antifungal agents, S4
- Syphilis, role of fibronectin in pathogenesis, S372
- Systemic antifungal agents, antimicrobial spectrum of, S4
- T cells, role of helper and cytolytic in intracellular bacterial infections, S650
- Taenia solium* in neurocysticercosis, 961
- Teichoic acid, role in adherence of *S. aureus* to epithelial cells, S341
- Tetracyclines  
 bacterial resistance worldwide, S244  
 for brucellosis, 531
- Thermometry, history of use in United States, 1193
- Thioester bond, role in inflammation, 97
- Tinea corporis, treatment with itraconazole, S119
- Tissue thromboplastin, macrophages and monocytes as source, S546
- Toxic shock syndrome, pathogenesis of menstrually related, S482
- Toxic shock syndrome toxin 1, production by *S. aureus*, suppression by magnesium, S482
- Toxoplasma gondii*, clinical spectrum of lymphadenopathy, 754
- Toxoplasmosis, diagnosis and serology, 775, 1055
- Transposons, 357
- Travelers' diarrhea, due to rotavirus, 461
- Treponema pallidum*, role of fibronectin in attachment, S372
- Trichinosis, case in infectious disease rounds, 804
- Trichophyton rubrum*, ultrastructure after itraconazole treatment, S33
- Trichosporon beigeli*, disseminated infection, 1013
- Trichosporon capitatum* fungemia and iv drug abuse [correspondence], 1202
- Trimethoprim, bacterial resistance worldwide, S244
- Trimethoprim-sulfamethoxazole  
 alternative to third-generation cephalosporins, S160  
 for brucellosis, 531  
 in glucose-6-phosphate dehydrogenase deficient patients, S218  
 for immunocompromised patients, S177  
 for serious nosocomial infections, S160  
 for *P. carinii* pneumonia, S184  
 iv treatment of pediatric infections, S168  
 iv treatment of infections, summary of symposium, S153  
 prophylaxis in abdominal, pelvic, and prostatic surgery, S211  
 for recurrent urinary tract infection, S195  
 symposium on iv therapy, S153-S229
- Trypanosoma cruzi*, role of fibronectin in disease, S391
- Tuberculosis  
 drug-resistant, treatment with rifabutin, 519  
 esophageal, 140  
 in Native Americans, pre-Columbian, 1180
- Tuberculous meningitis, mimicked by *Listeria*, 130
- Tumor necrosis factor  
 endotoxin effects, mediator of, S602  
 beneficial, S607  
 as inducer of colony-stimulating factor, S607
- Typhoid fever  
 in China, 823  
 control by immunization in Thailand, 841  
 treatment with cephalosporins, 719
- Typhus, in China, epidemiology, 823
- Urinary tract infection  
 recurrent, treatment with trimethoprim-sulfamethoxazole, S195  
 role of bacterial adherence in, 470
- Urine, inhibitors of interleukin-1, S594
- Uromodulin, interleukin-1 inhibitor, S594
- Uropathogens, adherence in urinary tract, 470

- Vaccine(s)  
  against encapsulated bacteria, 176  
  construction with *P. aeruginosa* toxin A, S644  
  typhoid, evaluation of heat/phenol inactivated, 841  
Vaccinia, introduction into United States, 1044  
Vaginal mycoses, oral treatment, S139  
Varicella-zoster virus, diagnosis and treatment of infection, 1020  
*Vibrio*, waterborne, infections, 54  
Viral disease, interferons in pathogenesis, prophylaxis, 243  
Viral glycoproteins, binding to fibronectin, S404  
Viral pathogenesis  
  encephalomyocarditis virus-induced diabetes mellitus in mice,  
    model, 912  
  role of fibronectin, S404  
Virulence determinants, *Shigella*, *Yersinia*, S450  
Waterborne pathogens  
  infections due to, in immunocompromised patients, 206  
  nonenteric, 54  
  rotavirus, 461  
Waterhouse, Benjamin, and smallpox vaccine, 1044  
Whooping cough, vaccine efficacy, 866  
Yellow fever, pathogenesis, diagnosis, and treatment, 165  
*Yersinia*, virulence determinants, S450  
*Yersinia enterocolitica*, calcium dependence and mechanisms of  
  virulence, 64

L

8

7

I

